Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Depreciation (2017 - 2025)

Aclaris Therapeutics has reported Accumulated Depreciation over the past 9 years, most recently at $5.0 million for Q3 2025.

  • Quarterly results put Accumulated Depreciation at $5.0 million for Q3 2025, up 6.5% from a year ago — trailing twelve months through Sep 2025 was $5.0 million (up 6.5% YoY), and the annual figure for FY2024 was $4.8 million, up 15.45%.
  • Accumulated Depreciation for Q3 2025 was $5.0 million at Aclaris Therapeutics, down from $5.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for ACRS hit a ceiling of $5.0 million in Q2 2025 and a floor of $2.9 million in Q1 2021.
  • Median Accumulated Depreciation over the past 5 years was $4.2 million (2023), compared with a mean of $4.1 million.
  • Biggest five-year swings in Accumulated Depreciation: grew 29.36% in 2021 and later increased 1.65% in 2024.
  • Aclaris Therapeutics' Accumulated Depreciation stood at $3.4 million in 2021, then rose by 18.92% to $4.0 million in 2022, then rose by 3.15% to $4.2 million in 2023, then rose by 15.45% to $4.8 million in 2024, then grew by 3.73% to $5.0 million in 2025.
  • The last three reported values for Accumulated Depreciation were $5.0 million (Q3 2025), $5.0 million (Q2 2025), and $4.9 million (Q1 2025) per Business Quant data.